NEW YORK (GenomeWeb News) – Alliance Global today said that it has signed an agreement with Amgen to provide cancer mutation testing in certain countries in the Middle East and Africa.

The partners have established a program to provide next-generation sequencing-based screening to identify colorectal cancer patients who have mutations in the RAS family of genes. They will utilize Illumina's MiSeqDx platform in screening the patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.